SMS Pharmaceuticals Ltd.
NSE: SMSPHARMA · Pharmaceuticals · sector
₹417.85NSE close 2026-10-26
Key numbers
Market cap₹3,913 cr
Price₹417.85
52w high / low₹494 / ₹270
P/E37.2xSector median 27.9x
P/B5.0xSector median 2.9x
Book value₹83.9
Dividend yield0.09%Sector median 0.48%
ROE14.4%Sector median 11.7%
ROCE12.4%Sector median 12.3%
OPM19.2%Sector median 14.0%
Debt / equity0.46xSector median 0.16x
EV/EBITDA24.5xSector median 18.6x
Interest cover6.3x
Current ratio1.81x
Sales growth 3y+19.3%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹46 cr vs borrowings ₹365 cr (FY26): borrowings are higher by ₹319 cr.
- Borrowings rose in each of the last 3 years (₹253 cr → ₹365 cr).
- Operating profit covered interest 6.3x in the last 12 months.
- 17.99% of the promoters' shares are pledged (12.2% of all shares).
- Operating cash flow was below net profit in 2 of the last 5 years (FY26, FY22).
- Revenue was higher than a year earlier in 3 of the last 4 quarters.
- Other income was 9% of net profit in the last 12 months.
- Debtor days went from 122 (FY24) to 89 (FY26).
- Dividend paid in 5 of the last 5 financial years.
- Price ₹417.85 on 2026-10-26: -15.5% from the 52-week high, +54.7% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹474.05 · low ₹183.25
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 197 | 173 | 248 | 196 | 242 | 210 | 238 | 207 |
| EBITDA | 31 | 33 | 41 | 39 | 48 | 44 | 40 | 41 |
| OPM % | 16.0% | 19.2% | 16.4% | 20.1% | 19.9% | 20.7% | 16.8% | 19.8% |
| Other income | 1 | 2 | 1 | 1 | 1 | 4 | 3 | 2 |
| Net profit | 14 | 18 | 120 | 20 | 25 | 23 | 33 | 21 |
| EPS (₹) | 1.69 | 2.15 | 2.40 | 2.31 | 2.84 | 2.59 | 3.58 | 2.23 |
| Revenue YoY | +23.2% | +21.4% | -4.1% | +5.6% | ||||
| Profit YoY | +79.5% | +28.5% | -72.4% | +2.0% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 520 | 522 | 709 | 783 | 887 | 898 |
| EBITDA | 114 | 54 | 117 | 139 | 171 | 173 |
| Net profit | 62 | -7 | 50 | 69 | 102 | 103 |
| EPS (₹) | 7.35 | -0.83 | 5.89 | 8.16 | 11.15 | 11.24 |
| Revenue growth | +0.4% | +35.9% | +10.4% | +13.3% | +10.2% | |
| Profit growth | -111.3% | – | +37.7% | +48.8% | -40.5% | |
| Dividend / share (₹) | 0.30 | 0.30 | 0.30 | 0.40 | 0.40 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +19.3% | +9.5% | +10.2% |
| Net profit | – | +10.3% | -40.5% |
| EPS | – | +8.6% | – |
| Share price | – | +18.6% (2y) | +50.2% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 461 | 536 | 640 | 786 |
| Borrowings | – | 253 | 280 | 311 | 365 |
| Cash & equivalents | – | 7 | 36 | 42 | 46 |
| Total assets | – | 880 | 1,034 | 1,153 | 1,362 |
| Fixed assets | – | 410 | 434 | 531 | 531 |
| Capital work in progress | – | 33 | 30 | 35 | 122 |
| Investments | – | 11 | 11 | 12 | 26 |
| Receivables | – | 148 | 236 | 203 | 216 |
| Inventory | – | 224 | 234 | 285 | 351 |
| Payables | – | 113 | 151 | 114 | 120 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 40 | 22 | 50 | 82 | 59 |
| Cash from investing | -27 | -30 | -52 | -123 | -131 |
| Cash from financing | -7 | -32 | 31 | 47 | 76 |
| Capex | 27 | 30 | 52 | 123 | 131 |
| Free cash flow | 13 | -7 | -2 | -42 | -71 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | -1.5% | 9.3% | 10.7% | 13.0% |
| ROCE % | – | 3.8% | 11.0% | 11.7% | 12.1% |
| Debtor days | – | 104 | 122 | 95 | 89 |
| Inventory days | – | 243 | 201 | 238 | 260 |
| Payable days | – | 123 | 130 | 95 | 89 |
| Cash conversion cycle (days) | – | 224 | 193 | 238 | 260 |
| Working capital days | – | 109 | 104 | 107 | 117 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 68.07% |
| FIIs | 1.18% |
| DIIs | 0.20% |
| of which Mutual funds | 0.00% |
| Public (non-institutions) | 30.56% |
| Quarter | Mar 2025 | Jun 2025 | Sep 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 66.26% | 66.26% | 68.07% | 68.07% | 68.07% | 68.07% | 68.07% | 68.07% |
| Promoter group | % |
|---|---|
| Ramesh Babu Potluri | 19.38% |
| Vamsi Krishna Potluri | 16.90% |
| Hima Bindu Potluri | 16.03% |
| Potluri Infra Projects LLP | 9.45% |
| Trilok Potluri | 5.01% |
| Potluri Laboratories Private Limited | 1.20% |
| TVT Infracon LLP | 0.11% |
| Public holders above 1% | % |
|---|---|
| Aniruddh Mundra | 1.84% |
| Venkata Subbaraju Penmatsa HUF | 1.60% |
| Alpana Mundra | 1.50% |
| Venkata Praveen Talluri | 1.41% |
| Sudeepthi Gopineedi | 1.41% |
34,904 shareholders. Pledged: 17.99% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| SMSPHARMA | ₹3,913 cr | 37.2x | 5.0x | 14.4% | 12.4% | 19.2% | +19.3% | 0.09% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-22 | Dividend | Dividend - Re 0.40 Per Share |
| 2025-09-22 | Dividend | Dividend - Re 0.40 Per Share |
| 2024-09-23 | Other | Annual General Meeting |
| 2024-09-23 | Dividend | Dividend - Rs 0.40 Per Share |
| 2023-09-22 | Other | Annual General Meeting |
| 2023-09-22 | Dividend | Dividend - Re 0.30 Per Share |
| 2022-09-22 | Other | Annual General Meeting |
| 2022-09-22 | Dividend | Dividend - Re 0.30 Per Share |
| 2021-09-22 | Dividend | Annual General Meeting/ Dividend Rs 0.30 Per Share |
| 2020-09-17 | Other | Annual General Meeting |
| 2020-03-26 | Dividend | Interim Dividend - Rs 0.25 Per Share |
| 2019-09-19 | Dividend | Dividend - Rs 0.25 Per Share |
| 2018-09-11 | Dividend | Annual General Meeting/Dividend Re 0.25 Per Share |
| 2017-09-20 | Dividend | Annual General Meeting/Dividend - Rs 0.20 Per Share |
| 2017-06-22 | Restructuring | Scheme Of Arrangement |
| 2016-09-22 | Dividend | Dividend Re 0.20 Per Share |
| 2015-12-17 | Split | Face Value Split (Sub-Division) - From Rs 10/- Per Share To Re 1/- Per Share |
| 2015-09-22 | Dividend | Annual General Meeting/ Dividend - Rs 2/- Per Share |
| 2014-09-23 | Dividend | Annual General Meeting And Dividend Rs.2/- Per Share |
| 2013-09-23 | Dividend | Annual General Meeting / Dividend - Rs 2 Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Manufacturing: Manufacture of Active Pharmaceutical Ingredients (APIs)
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | SMSPHARMA |
| BSE code | 532815 |
| ISIN | INE812G01025 |
| Face value | ₹1.0 |
| Incorporated | 1987-12-14 |
| Website | www.smspharma.com |
| Plants (India / abroad) | 3 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.